Involvement of kynurenines in Huntington's disease and stroke-induced brain damage

被引:38
作者
Stone, Trevor W. [1 ]
Forrest, Caroline M. [1 ]
Stoy, Nicholas [2 ]
Darlington, L. Gail [3 ]
机构
[1] Univ Glasgow, Inst Neurosci & Psychol, Glasgow G12 8QQ, Lanark, Scotland
[2] Royal Hosp Neurodisabil, London SW15 3SW, England
[3] Ashtead Hosp, Dept Med, Ashtead KT21 2SB, Surrey, England
关键词
Tryptophan; Kynurenine; Kynurenic acid; Quinolinic acid; Huntington's disease; Stroke; Neurodegeneration; Cognition; INDOLEAMINE 2,3-DIOXYGENASE ACTIVITY; CONVERT L-TRYPTOPHAN; NEURONAL CELL-DEATH; LEUKOCYTE ANTIGEN-G; HLA-G EXPRESSION; QUINOLINIC ACID; 3-HYDROXYANTHRANILIC ACID; PATHWAY METABOLISM; IMMUNE ACTIVATION; OXIDATIVE STRESS;
D O I
10.1007/s00702-011-0676-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Several components of the kynurenine pathway of tryptophan metabolism are now recognised to have actions of profound biological importance. These include the ability to modulate the activation of glutamate and nicotinic receptors, to modify the responsiveness of the immune system to inflammation and infection, and to modify the generation and removal of reactive oxygen species. As each of these factors is being recognised increasingly as contributing to major disorders of the central nervous system (CNS), so the potentially fundamental role of the kynurenine pathway in those disorders is presenting a valuable target both for understanding the progress of those disorders and for developing potential drug treatments. This review will summarise some of the evidence for an important contribution of the kynurenines to Huntington's disease and to stroke damage in the CNS. Together with preliminary evidence from a study of kynurenine metabolites after major surgery, an important conclusion is that kynurenine pathway activation closely reflects cognitive function, and may play a significant role in cognitive ability.
引用
收藏
页码:261 / 274
页数:14
相关论文
共 140 条
[111]  
STONE TW, 1993, PHARMACOL REV, V45, P309
[112]   Kynurenines in the CNS: from endogenous obscurity to therapeutic importance [J].
Stone, TW .
PROGRESS IN NEUROBIOLOGY, 2001, 64 (02) :185-218
[113]   QUINOLINIC ACID - A POTENT ENDOGENOUS EXCITANT AT AMINO-ACID RECEPTORS IN CNS [J].
STONE, TW ;
PERKINS, MN .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1981, 72 (04) :411-412
[114]   Endogenous kynurenines as targets for drug discovery and development [J].
Stone, TW ;
Darlington, LG .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (08) :609-620
[115]   MOVEMENT DISORDER FOLLOWING EXCITOTOXIN LESIONS IN PRIMATES [J].
STOREY, E ;
CIPOLLONI, PB ;
FERRRANTE, RJ ;
KOWALL, NW ;
BEAL, MF .
NEUROREPORT, 1994, 5 (10) :1259-1261
[116]   Tryptophan metabolism and oxidative stress in patients with Huntington's disease [J].
Stoy, N ;
Mackay, GM ;
Forrest, CM ;
Christofides, J ;
Egerton, M ;
Stone, TW ;
Darlington, LG .
JOURNAL OF NEUROCHEMISTRY, 2005, 93 (03) :611-623
[117]  
Tabrizi SJ, 2000, ANN NEUROL, V47, P80
[118]   EFFECTS OF STRIATAL EXCITOTOXICITY ON HUNTINGTON-LIKE IMMUNOREACTIVITY [J].
TATTER, SB ;
GALPERN, WR ;
HOOGEVEEN, AT ;
ISACSON, O .
NEUROREPORT, 1995, 6 (08) :1125-1129
[119]  
Tauber E, 2010, J BIOL CHEM IN PRESS
[120]   Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells:: Mediation of suppression by tryptophan metabolites [J].
Terness, P ;
Bauer, TM ;
Röse, L ;
Dufter, C ;
Watzlik, A ;
Simon, H ;
Opelz, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (04) :447-457